Analyst Conference Call Notes by William Meyers

Biotechnology Investor Aids

Celsion
CLSN

conference date: November 14, 2017 @ 8:00 AM Pacific Time

Independent NIH Analysis of Thermodox plus RFA for Liver Cancer [September 12, 2016]

RFA plus lyso-thermosensitive liposomal doxorubicin [June 10, 2016] all the details on Thermodox studies

2017
 
May 12, 2017
August 15, 2017
Nov. 14, 2017
 
2016
 
08/15/2016
11/10/2016
03/16/2017
 

Celsion (CLSN) is a -stage biotechnology company specializing in cancer therapies. Its lead product is ThermoDox.

Celsion web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2016 William P. Meyers